fluenz
medimmune llc - reassortant gripo virusas (gyvos praskiestos) iš šių padermių:a/california/7/2009 (h1n1)pdm09, kaip padermė, a/victoria/361/2011 (h3n2) virusas, kaip kamienas, b/masačusetsas/2/2012, pavyzdžiui, įtampą - influenza, human; immunization - vakcinos - profilaktikai gripo asmenims 24 mėnesių iki mažiau kaip 18 metų amžiaus. naudoti fluenz turėtų būti pagrįstas oficialiomis rekomendacijomis.
acilib
sia meda pharma - pantoprazolas - skrandyje neirios tabletės - 20 mg - pantoprazole
controloc
takeda gmbh - pantoprazolas - skrandyje neirios tabletės - 20 mg; 40 mg - pantoprazole
ipraalox
opella healthcare france sas - pantoprazolas - skrandyje neirios tabletės - 20 mg - pantoprazole
lanzostad
stada arzneimittel ag - lansoprazolas - skrandyje neirios kietosios kapsulės - 30 mg; 15 mg - lansoprazole
omediprol
teva b.v. - omeprazolas - skrandyje neirios kietosios kapsulės - 10 mg; 20 mg - omeprazole
pantoprazole actavis
teva b.v. - pantoprazolas - skrandyje neirios tabletės - 20 mg; 40 mg - pantoprazole
blincyto
amgen europe b.v. - blinatumomabas - prekursorių ląstelių limfoblastinė leukemija-limfoma - antinavikiniai vaistai - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. Žr. 4 skyrius. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
pexion
boehringer ingelheim vetmedica gmbh - imepitoinas - kiti antiepileptics, antiepileptics - Šunys - dėl dažnumo sumažinimo bendrųjų traukuliai dėl idiopatinė epilepsija šunys, naudoti, atidžiai įvertinus alternatyvių gydymo galimybės.